Literature DB >> 15040557

CV8, a new combination of dihydroartemisinin, piperaquine, trimethoprim and primaquine, compared with atovaquone-proguanil against falciparum malaria in Vietnam.

Phan T Giao1, Peter J de Vries, Le Q Hung, Tran Q Binh, Nguyen V Nam, Piet A Kager.   

Abstract

OBJECTIVES: To study a new combination, based on dihydroartemisinin and piperaquine (CV8) and atovaquone/proguanil (Malarone) for treatment of uncomplicated falciparum malaria in Vietnam.
METHODS: Vietnamese adults with falciparum malaria were allocated randomly to treatment with dihydroartemisinin/piperaquine/trimethoprim/primaquine 256/2560/720/40 mg (CV8, n = 84) or Malarone 3000/1200 mg (n = 81), both over 3 days. Patients were followed-up for 28 days.
RESULTS: All patients recovered rapidly. The mean (95% CI) parasite elimination half-life of CV8 was 6.8 h (6.2-7.4) and of Malarone 6.5 h (6.1-6.9) (P = 0.4). Complete parasite clearance time was 35 (31-39) and 34 h (31-38) (P = 0.9). The 28-day cure rate was 94% and 95%, respectively (odds ratio 0.84, 95% CI 0.18-3.81). No significant side-effects were found.
CONCLUSION: CV8 and Malarone are effective combinations against multi-drug resistant falciparum malaria. CV8 has the advantage of a low price.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15040557     DOI: 10.1046/j.1365-3156.2003.01180.x

Source DB:  PubMed          Journal:  Trop Med Int Health        ISSN: 1360-2276            Impact factor:   2.622


  18 in total

1.  Atovaquone-proguanil for treating uncomplicated Plasmodium falciparum malaria.

Authors:  Andrew Blanshard; Paul Hine
Journal:  Cochrane Database Syst Rev       Date:  2021-01-15

Review 2.  Piperaquine: a resurgent antimalarial drug.

Authors:  Timothy M E Davis; Te-Yu Hung; Ing-Kye Sim; Harin A Karunajeewa; Kenneth F Ilett
Journal:  Drugs       Date:  2005       Impact factor: 9.546

3.  Pharmacokinetics of piperaquine after repeated oral administration of the antimalarial combination CV8 in 12 healthy male subjects.

Authors:  Daniel Röshammar; Trinh Ngoc Hai; Sofia Friberg Hietala; Nguyen Van Huong; Michael Ashton
Journal:  Eur J Clin Pharmacol       Date:  2006-03-29       Impact factor: 2.953

Review 4.  Primaquine or other 8-aminoquinoline for reducing Plasmodium falciparum transmission.

Authors:  Patricia M Graves; Hellen Gelband; Paul Garner
Journal:  Cochrane Database Syst Rev       Date:  2015-02-19

Review 5.  Atovaquone-proguanil for treating uncomplicated malaria.

Authors:  A Osei-Akoto; L Orton; S P O Owusu-Ofori
Journal:  Cochrane Database Syst Rev       Date:  2005-10-19

6.  A phase III, randomized, non-inferiority trial to assess the efficacy and safety of dihydroartemisinin-piperaquine in comparison with artesunate-mefloquine in patients with uncomplicated Plasmodium falciparum malaria in southern Laos.

Authors:  Mayfong Mayxay; Sommay Keomany; Maniphone Khanthavong; Phoutthalavanh Souvannasing; Kasia Stepniewska; Tiengthong Khomthilath; Siamphay Keola; Tiengkham Pongvongsa; Samlane Phompida; David Ubben; Neena Valecha; Nicholas J White; Paul N Newton
Journal:  Am J Trop Med Hyg       Date:  2010-12       Impact factor: 2.345

7.  Longitudinal survey of Plasmodium falciparum infection in Vietnam: characteristics of antimalarial resistance and their associated factors.

Authors:  Rie Isozumi; Haruki Uemura; Duc Dao Le; Van Hanh Truong; Duc Giang Nguyen; Viet Vien Ha; Quang Phuc Bui; Van Tuan Nguyen; Shusuke Nakazawa
Journal:  J Clin Microbiol       Date:  2009-11-04       Impact factor: 5.948

Review 8.  Primaquine or other 8-aminoquinoline for reducing P. falciparum transmission.

Authors:  Patricia M Graves; Hellen Gelband; Paul Garner
Journal:  Cochrane Database Syst Rev       Date:  2014-06-30

9.  Delayed parasite clearance after treatment with dihydroartemisinin-piperaquine in Plasmodium falciparum malaria patients in central Vietnam.

Authors:  Kamala Thriemer; Nguyen Van Hong; Anna Rosanas-Urgell; Bui Quang Phuc; Do Manh Ha; Evi Pockele; Pieter Guetens; Nguyen Van Van; Tran Thanh Duong; Alfred Amambua-Ngwa; Umberto D'Alessandro; Annette Erhart
Journal:  Antimicrob Agents Chemother       Date:  2014-09-15       Impact factor: 5.191

10.  MMV in partnership: the Eurartesim® experience.

Authors:  David Ubben; Elizabeth M Poll
Journal:  Malar J       Date:  2013-06-19       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.